VS-6063

Drug identity checked against registry records

Also recorded as defactinib

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsNCT02004028VSTMPhase 2Terminated2019-06-19Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.